Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6A7KB
|
|||
| Drug Name |
ENV-101
|
|||
| Synonyms |
Taladegib
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [1] | |
| Company |
Endeavor BioMedicines
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hedgehog signaling pathway (HS pathway) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04968574) A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health. | |||
| REF 2 | Development of taladegib as a sonic hedgehog signaling pathway inhibitor. Arch Pharm Res. 2017 Dec;40(12):1390-1393. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.